Transgene - Preclinical Results Showing TG6050, a Novel Onco

Invir.IO® based oncolytic virus TG6050, is armed with IL-12 and an anti-CTLA4 antibody. A Phase I trial (Delivir) recently started enrolling patients with advanced non-small cell lung cancer (NSCLC)

Related Keywords

United States , Copenhagen , Køavn , Denmark , American , Transgene Euronext , Lucie Larguier , Ben Brahim , Astrazeneca , Corporate Communications , Twitter , American Association For Cancer Research , Euronext Paris , American Association , Cancer Research , Annual Meeting , Phasei Delivir , Artificial Intelligence , Risk Factors , Universal Registration Document , Transgene , Reclinical , Results , Showing , G6050 , Novel , Ncolytic , Virus , Induces , Humor , Regression , Deactivating , Yinnate , Adaptive , Immune , Responses , Resented , Racr ,